Showing results (51-60 of 349) with videos related to
Sort By:
Pageof 35
Cancer Management and Research|December 29, 2010
Management of metastatic renal cell carcinoma in patients with poor prognosisAndrea Bullock, David F McDermott, Michael B AtkinsThe Oncologist|May 1, 2019
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?Xin Gao, David F McDermott, M Dror MichaelsonExpert Review of Anticancer Therapy|June 14, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approvalHollis Viray, David F McDermott, David J EinsteinCancer Journal (Sudbury, Mass.)|January 24, 2017
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern EraBenjamin Izar, Meredith M Regan, David F McDermottClinical Genitourinary Cancer|December 5, 2017
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy EraSandy T Liu, Gavin Hui, Colleen Mathis, et al.World Journal of Urology|May 4, 2020
VEGF inhibition in urothelial cancer: the past, present and futureSanaz Ghafouri, Aaron Burkenroad, Morgan Pantuck, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 27, 2024
Molecular Diversity of Embryonic-Type Neuroectodermal Tumors Arising From Testicular Germ Cell TumorsYang Zong, Rongrong Huang, Mireille Bitar, et al.Clinical Therapeutics|April 1, 2015
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M Mahoney, Gordon J Freeman, David F McDermottClinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B AtkinsDrug Design, Development and Therapy|February 9, 2018
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinomaIzak Faiena, Amy L Cummings, Anna M Crosetti, et al.Pageof 35